Clinical Trials Logo

Clinical Trial Summary

Polymyositis and dermatomyositis are rare inflammatory systemic conditions. Reduced muscle function is a cardinal symptom and lung involvement is very common. Knowledge of heart involvement in these patients is very limited, as is knowledge of exercise effects in recent onset, active disease.

The aim of this project is to investigate effects of high-intensity interval training (HIIT) compared to standard low-intensity home exercise as to tolerance, physical capacity, quality of life, depression, disease activity, inflammation, muscle mass/fat mass, muscle metabolism and heart function in patients with recent onset, active polymyositis and dermatomyositis.

This is a randomized controlled trial. Muscle biopsies are taken at time of diagnosis and after 12 weeks of exercise. Muscle biopsies will be analyzed as to baseline kynurenine pathway, calcium release, gene expression and inflammatory infiltrates and as to changes in these parameters following exercise. Muscle function (primary outcome), maximal oxygen uptake, muscle mass/fat mass, disease activity, systolic and diastolic heart function, as well as quality of life and depression is measured at baseline and after 12 weeks of exercise. After all assessments, patients are randomized to HIIT or standard low-intensity home exercise.

The HIIT group will perform 6 sets of 30-60 second biking bouts reaching 85-100% of maximal heart rate, in combination with strength training, three days a week for 12 weeks. The control group will perform a standardized home exercise program five days a week for 12 weeks. After 12 weeks, all assessments are preformed again. If the HIIT is well tolerated, patients in the control group will be invited to HIIT exercise according to the same protocol. Clinical assessments will be performed at 3, 6 and 9 months follow-up in an open extension.

This study will improve our understanding of heart function, muscle metabolism as well as tolerance and effects of intensive exercise as well as heart function early in the disease course and could also improve treatment and prognosis in patients with polymyositis and dermatomyositis.


Clinical Trial Description

Patients randomized to the HIIT protocol will train three days a week for 12 weeks. Before exercise start participants will rate self-reported pain and fatigue on a visual analogue scale and describe in own words information about possible changes in medication dose, any side effects from medication as well as possible negative and positive effects from previous exercise sessions, as well as physical activities performed since the previous exercise session. Each exercise session starts with a 5-minut warm-up on about 50% of maximal heart rate. Each HIIT set is between 30-60 seconds where loads are increased and the participant bikes as fast as possible with the goal of reaching >85% of maximal heart rate. During the 2-minuts rest in-between HIIT sets the participant will rate self-reported exertion using the Borg CR-10, 0-10 scale and the Borg RPE scale, 6-20.

When initiating the exercise period, participants start on three HIIT sets on a lower intensity, gradually increasing to goal intensity during the first two weeks. Then the number of sets are gradually increased to six sets.

After completing six HIIT sets the participants perform one set of 10 voluntary repetitions maximum (VRM) resistance training of the deltoids using free weights and of the quadriceps using free weights or a quadriceps curl machine, depending on degree of muscle weakness. Every other week a new 10 VRM is tested and training loads are adapted. After completing each set, the participant rates perceived muscle exertion on the Borg CR-10 scale. The program is ended with stretching of trained muscle groups and rating of overall exertion during the exercise session on the Borg RPE-scale.

Participants randomized to the control group will perform a standardized home exercise program on an easy-to moderate intensity adapted to initial muscle weakness, five days a week for 12 weeks. The program includes tasks for muscle groups targeted by myositis and takes about 15 minutes to perform. In combination with the home exercise program the participants walks 15 minutes on 60% of maximal heart rate. Participants fill out an exercise diary commenting on loads and number of repetitions for each task.

Participants in both groups ware a Polar 330A heart rate monitor during each training session. By synchronizing to a computer program all exercise data are stored in a cloud data base and can be monitored regularly by the project investigator. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03324152
Study type Interventional
Source Karolinska University Hospital
Contact Helene Alexanderson, PhD, Ass.prof
Phone +46 8 517745 96
Email helene.alexanderson@sll.se
Status Recruiting
Phase N/A
Start date October 1, 2017
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05833711 - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy Phase 2
Completed NCT01906372 - Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Phase 2
Completed NCT01813617 - Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis N/A
Completed NCT01165008 - Anakinra in Myositis Phase 2/Phase 3
Completed NCT00004357 - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Phase 2
Recruiting NCT05832034 - Add-on Intravenous Immunoglobulins in Early Myositis Phase 2
Recruiting NCT05979441 - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy Phase 3
Not yet recruiting NCT05027152 - Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties N/A
Active, not recruiting NCT04723303 - Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) Early Phase 1
Completed NCT03267277 - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Phase 2/Phase 3
Recruiting NCT05437263 - A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Phase 3
Active, not recruiting NCT04044690 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) Phase 3
Recruiting NCT05523167 - A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Phase 2/Phase 3
Not yet recruiting NCT06004817 - Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Completed NCT02043548 - Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Phase 2
Completed NCT03414086 - Predictor of Clinical Response to Acthar in Myositis
Completed NCT04628936 - Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. Phase 2
Recruiting NCT03293615 - Exercise Capacity of Patients With Dermatomyosis N/A
Completed NCT06002750 - Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Inflammation
Completed NCT02612857 - Trial of IMO-8400 in Adult Patients With Dermatomyositis Phase 2